Bayer investors are being pulled in two directions at once. On one side sits a pharma pipeline that just notched two regulatory victories in a matter of days; on the other, a fresh US courtroom battle that could redefine the company’s legal exposure for years to come. The tug-of-war played out in the share price this week, with the stock slipping 2.7% to EUR 47.75 on Wednesday as a broadly weaker market added to the pressure.
The wider backdrop did the stock no favors. Stubborn eurozone inflation, climbing oil prices and rising bond yields dragged the DAX firmly into the red, and Bayer moved with it. Yet the sharper focus was on Missouri, where a glyphosate case against subsidiary Monsanto opened the same day. Three plaintiffs allege the company failed to adequately test the herbicide Roundup before bringing it to market — a line of argument distinct from the warning-label claims that have dominated prior litigation. Observers therefore view the proceeding as a bellwether for how far future liability might stretch.
A Quarter That Looks Softer Than It Sounds
Attention is now turning to whether the underlying business can absorb that legal noise. Deutsche Bank Research weighed in on Tuesday, with analyst Virginie Boucher-Ferte projecting operating sales growth of 1.3% year over year for the third quarter. Operating profit, however, is expected to fall 10%. The culprit is not weak demand so much as a tough comparison: unusually favorable one-off effects flattered the agricultural business in the prior-year quarter.
That distinction matters. Revenue growth loses much of its force when profitability retreats by a double-digit margin, and institutional investors are treating margin stabilization as the real test of the investment case. The balance sheet needs to stay sturdy enough to carry parallel burdens without crimping strategic room to maneuver. Deutsche Bank reaffirmed its buy rating and a EUR 60 price target, underscoring the theoretical headroom relative to current levels.
Two Regulatory Wins in Rapid Succession
The bull case rests heavily on the pharmaceutical pipeline, and it received concrete reinforcement this week. On Monday, the FDA granted priority review status to Lynkuet (Elinzanetant) for an additional indication — treating moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer. Accelerated review shortens the path to a potential market launch considerably.
A day later, subsidiary BlueRock Therapeutics secured orphan-drug status for its cell therapy candidate Lemiretprocel. The FDA designation covers retinitis pigmentosa and cone-rod dystrophy, while the EMA granted equivalent status for certain inherited retinal diseases. Such designations carry expanded market and development privileges. Should revenue from these new introductions outweigh softness elsewhere, the stock’s upside case gains fresh traction.
Should investors sell immediately? Or is it worth buying Bayer?
Financing has been addressed in parallel. On September 23, Bayer placed new hybrid bonds totaling EUR 2 billion, lifting its total outstanding hybrid volume to EUR 6.55 billion. The two tranches each run 30 years, carrying coupons of 5.75% and 6.25%. The refinancing buys management flexibility, though it also locks in substantial interest obligations for years ahead.
Legal Overhang and a Cautious Institutional Footprint
Against that optimism stand hard legal and institutional risks. Beyond the expected 10% drop in third-quarter operating profit, US litigation uncertainty remains a persistent drag. Reuters reports the company is pursuing a USD 7.25 billion settlement to resolve nearly all existing and future Roundup claims, but a court has yet to sign off — and the Missouri plaintiffs are not part of the proposed deal. Bayer rejects the allegations outright, yet the case demonstrates that individual risks can flare up outside any global settlement.
Should proceedings drag on or produce costly judgments, the stock’s risk premium could widen again. A legal defeat built on novel claim theories would seriously undermine confidence in a final clean-up of legacy liabilities. Large investors are already treading carefully: a voting-rights filing on Tuesday showed asset manager Amundi trimming its Bayer stake, with its holding falling from 3.04% to 2.90% after crossing a threshold on September 23. Continued withdrawal of institutional capital could weigh on the share price even if operating data hold steady. The macroeconomic climate for cyclical agrochemical products remains fragile too, with higher rates making refinancing more expensive and volatile end markets squeezing margins.
Chart Levels and the November Verdict
Technically, the picture stays constructive as long as the stock avoids a decisive break below key trend lines. At EUR 47.75, the shares sit comfortably above their 200-day moving average of EUR 43.00. Defending that level keeps the medium-term uptrend alive; a significant slide beneath it would hand the bears the upper hand. The stock is up 29% since the start of the year, recovering part of its earlier valuation discounts.
The next hard catalyst is already circled. On November 3, Bayer publishes full third-quarter results. That report will settle whether the operating business is holding pace with expectations — or whether the US litigation seizes the narrative once more.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from October 1 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 1.
Bayer: Buy or sell? Read more here...
